SYNTHESIS, STRUCTURE, AND BIOLOGICAL ACTIVITY OF COORDINATION COMPOUNDS
1423
6. Spek, A.L., J. Appl. Cryst., 2003, vol. 36, p. 7. doi
or N-(4-methoxyphenyl)hydrazine carbothioamide (in
the case of HL3) in the 1 : 1 molar ratio.
10.1107/S0021889802022112
7. Nakamoto, K., Infrared Spectra of Inorganic and Coordi-
nation Compounds, New York: Wiley Interscience, 1963.
Compound HL2. Yield 65%, mp 201–203°С. Found,
%: С 48.51; Н 3.60; N 17.30; S 9.81. C13H12N4O4S. Cal-
culated, %: С 48.75; Н 3.78; N 17.49; S 10.01.
Compound HL3. Yield 70%, mp 213–215°С. Found,
%: С 48.67; Н 3.68; N 17.29; S 9.80. C13H12N4O4S. Cal-
culated, %: С 48.75; Н 3.78; N 17.49; S 10.01.
8. Gulea, A.P., Spynu, S.N., Tsapkov, V.I., and Poirier, D.,
Russ. J. Gen. Chem., 2008, vol. 78, no. 8, p. 984. doi
10.1134/S1070363208050253
9. Gulea, A.P., Prisacari, V.I. , Tsapkov, V.I., Buracheva, S.A.,
Spynu1, S.N., Bezhenari, N.P., Poirier, D., and Roy, J.,
Pharm. Chem. J., 2007, vol. 41, no. 11, p. 596. doi
10.30906/0023-1134-2007-41-11-29-32
Thioamides HL1–3 were readily soluble in DMF and
DMSO as well as in alcohols (at heating).
Dichlorobis{N-(2-methoxyphenyl)-2-[(5-nitro-fu-
ryl)methylene]hydrzxine carbothioamido}cobalt (1).
Asolution of 10 mmol of cobalt(II) chloride hexahydrate
in 20 mL of ethanol was added to a solution of 20 mmol
of N-(2-methoxyphenyl)-2-[(5-nitrofuryl)methylene]-
hydrazine carbothioamide (HL1) in 30 mL of ethanol
at stirring and heating (50–55°С). The reaction mixture
was refluxed during 50–60 min, cooled to ambient, and
slowly evaporated. Dark brown precipitate was filtered
off, washed with small amount of ethanol, and dried in
air to constant mass.
10. Gulea, A.P., Prisacari, V.I., Tsapkov, V.I., Buracheva, S.A.,
Spynu, S.N., and Bezhenari, N.P., Pharm. Chem. J., 2008,
vol. 42, no. 11, p. 326. doi 10.30906/0023-1134-2008-42-
6-19-21
11. Pahontu, E., Fala, V., Gulea, A., Poirier, D., Tsapkov,
V., and Rosu, T., Molecules, 2013, no. 18, p. 8812. doi
10.3390/molecules18088812
12. Pahontu, E., Julea, F., Rosu, T., Purcarea, V., Chumakov,
Yu., Petrenko, P., and Gulea, A., J. Cell. Mol. Med., 2015,
vol. 19, no. 4, p. 865. doi 10.1111/jcmm.12508
13. Pathan, A.H., Bakale, R.P., Naik, G.N., Frampton, C.S.,
and Gudasi, K.B., Polyhedron, 2012, vol. 34, no. 1, p. 149.
doi 10.1016/j.poly.2011.12.033
Complexes 2–18 were prepared similarly.
CONFLICT OF INTERESTS
14. CrysAlisPro, Version 1.171.33.52 (release 06-11-2009
CrysAlis171.NET). Oxford Diffraction Ltd.
No conflict of interests was declared by the authors.
REFERENCES
15. Sheldrich, G.M., Acta Cryst. (A), 2008, vol. 64, p. 112. doi
10.1107/S0108767307043930
16. Macrae, C.F., Edgington, P.R., McCabe, P., Pidcock, E.,
Shields, G.P., Taylor, R., Towler, M., and Van De Streek, J.,
J. Appl. Cryst., 2006, vol. 39, p. 453. doi 10.1107/
S002188980600731X
1. Mashkovskii, M.D., Lekarstvennye sredstva (Drugs),
Moscow: Novaya Volna, 2012.
2. Kalinowski, D.S. and Richardson, D.R., Pharmacol.
Rev., 2005, vol. 57, no. 4, p. 547. doi 10.1124/pr.57.4.2
17. Saswati, Dinda, R., Schmiesing, C., Sinn, E., Patil, Y.P.,
Nethaji, M., Stoeckli-Evans, H., and Acharyya, R.,
Polyhedron, 2013, vol. 50, p. 354. doi 10.1016/j.po-
ly.2012.11.031
3. Beraldo, H. and Gambino, D., Mini-Rev. Med. Chem.,
2004, vol. 4, no. 1, p. 31. doi 10.2174/ 1389557043487484
4. Ulkuseven, B., Bal-Demirci, T., Akkurt, M., Yalcin,
S.P., and Buyukgungor, O., Polyhedron, 2008, vol. 27,
p. 3646. doi 10.1016/j.poly.2008.08.024
18. Gulea, A., Poirier, D., Roy, J., Stavila, V., Bulimestru, I.,
Tapcov, V., Birca, M., and Popovschi, L., J. Enzyme
Inhib. Med. Chem., 2008, vol. 23, no. 6, p. 806. doi
101080/147563607017443002
5. Gulea, A.P., Lozan-Tyrshu, K.S., Tapcov, V.I., Korzha,
I.D., and Rudik, V.F., Russ. J. Gen. Chem., 2012, vol. 82,
no. 11, p. 1869. doi 10.1134/S1070363212110242
RUSSIAN JOURNAL OF GENERAL CHEMISTRY Vol. 89 No. 7 2019